High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana
Author(s) -
Kathleen E. Ryan,
Motswedi Anderson,
Ivayla E. Gyurova,
Lilliam Ambroggio,
Sikhulile Moyo,
Teresa K. Sebunya,
Joseph Makhema,
Richard Marlink,
Max Essex,
Rosemary Musonda,
Simani Gaseitsiwe,
Jason T. Blackard
Publication year - 2017
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofx195
Subject(s) - emtricitabine , medicine , hbsag , occult , hepatitis b virus , virology , hepatitis b , viral load , immunology , nucleoside analogue , tenofovir , lamivudine , human immunodeficiency virus (hiv) , virus , nucleoside , pathology , biology , biochemistry , alternative medicine
Occult HBV infection is quite common in HIV-infected patients in Botswana, although its impact on the course of HIV disease progression is unknown. The suppression of occult HBV DNA levels by tenofovir/emtricitabine suggests an effective therapeutic option, although the long-term suppressive abilities remain unstudied.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom